[The role of brachytherapy in the therapeutic strategy of vesico-prostatic rhabdomyosarcoma in children].
Because of its ballistic and physical characteristics, brachytherapy (BT) represents the optimal irradiation treatment in pediatric tumors, especially in prostate or bladder rhabdomyosarcoma. In a limited series of 15 children treated with BT (including three patients treated with salvage BT), 8 out of 9 patients surviving with NED benefited from conservative treatment among 12 patients treated with BT as first-line treatment. Sequelae were minimal consisting of one grade I cystitis and one asymptomatic vesical and ureteral reflux. BT allows administration of high doses to limited volumes sparing normal tissues. BT--whenever possible--represents the treatment of choice compared with external radiotherapy. Indications of BT depend on tumor accessibility and size (usually < or = 4 cm).
Haie-Meder
C
C
Service de Curiethérapie, Institut Gustave-Roussy, Villejuif.
Flamant
F
F
Revillon
Y
Y
Valayer
J
J
Gruner
M
M
Martelli
H
H
Habrand
J L
JL
Terrier-Lacombe
M J
MJ
Gerbaulet
A
A
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001918:Brachytherapy / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D015653:Cystectomy; D006801:Humans; D007223:Infant; D007496:Iridium Radioisotopes / Q000627:therapeutic use; D008297:Male; D009364:Neoplasm Recurrence, Local; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012208:Rhabdomyosarcoma / Q000532:radiotherapy*; D016879:Salvage Therapy; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000532:radiotherapy*
D007496:Iridium Radioisotopes
Place de la curiethérapie dans la stratégie thérapeutique des rhabdomyosarcomes vésico-prostatiques de l'enfant.